Synthetic biology in probiotic lactic acid bacteria: At the frontier of living therapeutics

Current Opinion in Biotechnology

Volumn 53, Issue , 2018, Pages 224-231

  Mays, Zachary JS ^a   Nair, Nikhil U ^a  

^a Tufts University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APPLICATION PROGRAMS; BACTERIA; MEDICAL APPLICATIONS; TARGETED DRUG DELIVERY;

BIOMEDICAL APPLICATIONS; FUTURE APPLICATIONS; INTERCONNECTIVITY; LACTIC ACID BACTERIA; MICROBIAL COMMUNITIES; SYNTHETIC BIOLOGY; THERAPEUTIC AGENTS; THERAPEUTIC SYSTEMS;

LACTIC ACID;

PREBIOTIC AGENT; PROBIOTIC AGENT;

BACTERIAL STRAIN; BACTERIUM DETECTION; BIOMEDICAL ENHANCEMENT; DEVELOPMENTAL GENETICS; DIET SUPPLEMENTATION; DRUG DEVELOPMENT; DRUG MECHANISM; DRUG TARGETING; ESCHERICHIA COLI; GENE EDITING; GENE EXPRESSION; GENE EXPRESSION SYSTEM; HEALTH IMPACT ASSESSMENT; HEALTH PROMOTION; HOMEOSTASIS; LACTIC ACID BACTERIUM; LACTOBACILLUS JENSENII; LACTOBACILLUS PLANTARUM; LACTOBACILLUS SAKEI; LACTOCOCCUS LACTIS; MEDICAL MICROBIOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SYNTHETIC BIOLOGY; GENE REGULATORY NETWORK; GENETICS; HUMAN; LACTOBACILLALES; METABOLISM; PROCEDURES;

GENE EDITING; GENE REGULATORY NETWORKS; HUMANS; LACTOBACILLALES; PROBIOTICS; SYNTHETIC BIOLOGY;

EID: 85045948387     PISSN: 09581669     EISSN: 18790429     Source Type: Journal    
DOI: 10.1016/j.copbio.2018.01.028     Document Type: Review

References (57)

1. Krishnan, S., Alden, N., Lee, K., Pathways and functions of gut microbiota metabolism impacting host physiology. Curr Opin Biotechnol 36 (2015), 137–145, 10.1016/j.copbio.2015.08.015.
2. Cano-Garrido, O., Seras-Franzoso, J., Garcia-Fruitós, E., Lactic acid bacteria: reviewing the potential of a promising delivery live vector for biomedical purposes. Microb Cell Fact, 14, 2015, 137, 10.1186/s12934-015-0313-6.
3. Kwok, L., Lactic acid bacteria and the human gastrointestinal tract. Zhang, H., Cai, Y., (eds.) Lact. Acid Bact. Fundam. Pract., 2014, Springer, Netherlands, Dordrecht, 375–441, 10.1007/978-94-017-8841-0_6.
4. Shafaghi, A., Pourkazemi, A., Khosravani, M., Fakhrie Asl, S., Amir Maafi, A., Atrkar Roshan, Z., Abaspour Rahimabad, J., The effect of probiotic plus prebiotic supplementation on the tolerance and efficacy of Helicobacter pylori eradication quadruple therapy: a randomized prospective double blind controlled trial. Middle East J Dig Dis 8 (2016), 179–188, 10.15171/mejdd.2016.30.
5. Use of probiotics in prevention and treatment of patients with Clostridium difficile infection. Best Pract Res Clin Gastroenterol 30 (2016), 111–118, 10.1016/J.BPG.2016.01.002.
6. Von Wright, A., (eds.) Lactic Acid Bacteria: Microbiological and Functional Aspects, edn 4, 2011, CRC Press, Boca Raton, FL, 10.1201/b11503.
7. Tauer, C., Heinl, S., Egger, E., Heiss, S., Grabherr, R., Tuning constitutive recombinant gene expression in Lactobacillus plantarum. Microb Cell Fact, 13, 2014, 150, 10.1186/s12934-014-0150-z.
8. Jensen, P.R., Hammer, K., The sequence of spacers between the consensus sequences modulates the strength of prokaryotic promoters. Appl Environ Microbiol 64 (1998), 82–87, 10.1002/bies.950100409.
9. Llull, D., Poquet, I., New expression system tightly controlled by zinc availability in Lactococcus lactis. Appl Environ Microbiol 70 (2004), 5398–5406, 10.1128/AEM.70.9.5398-5406.2004.
10. Mu, D., Montalbán-López, M., Masuda, Y., Kuipers, O.P., Zirex: a novel zinc-regulated expression system for Lactococcus lactis. Appl Environ Microbiol 79 (2013), 4503–4508, 10.1128/AEM.00866-13.
11. Linares, D.M., Alvarez-Sieiro, P., del Rio, B., Ladero, V., Redruello, B., Cruz Martin, M., Fernandez, M., Alvarez, M.A., Implementation of the agmatine-controlled expression system for inducible gene expression in Lactococcus lactis. Microb Cell Fact, 14, 2015, 10.1186/s12934-015-0399-x.
12. Heiss, S., Hörmann, A., Tauer, C., Sonnleitner, M., Egger, E., Grabherr, R., Heinl, S., Evaluation of novel inducible promoter/repressor systems for recombinant protein expression in Lactobacillus plantarum. Microb Cell Fact, 15, 2016, 50, 10.1186/s12934-016-0448-0.
13. Jørgensen, C.M., Vrang, A., Madsen, S.M., Recombinant protein expression in Lactococcus lactis using the P170 expression system. FEMS Microbiol Lett 351 (2014), 170–178, 10.1111/1574-6968.12351.
14. Miyoshi, A., Jamet, E., Commissaire, J., Renault, P., Langella, P., Azevedo, V., A xylose-inducible expression system for Lactococcus lactis. FEMS Microbiol Lett 239 (2004), 205–212, 10.1016/j.femsle.2004.08.018.
15. van Asseldonk, M., Simons, A., Visser, H., de Vos, W.M., Simons, G., Cloning, nucleotide sequence, and regulatory analysis of the Lactococcus lactis dnaJ gene. J Bacteriol 175 (1993), 1637–1644, 10.1128/JB.175.6.1637-1644.1993.
16. Sanders, J., Leenhouts, K., Haandrikman, A., Venema, G., Kok, J., Stress response in Lactococcus lactis: cloning, expression analysis, and mutation of the lactococcal superoxide dismutase gene. J Bacteriol 177 (1995), 5254–5260.
17. Benbouziane, B., Ribelles, P., Aubry, C., Martin, R., Kharrat, P., Riazi, A., Langella, P., Bermúdez-Humarán, L.G., Development of a Stress-Inducible Controlled Expression (SICE) system in Lactococcus lactis for the production and delivery of therapeutic molecules at mucosal surfaces. J Biotechnol 168 (2013), 120–129, 10.1016/j.jbiotec.2013.04.019.
18. Desmond, C., Fitzgerald, G.F., Stanton, C., Ross, R.P., Improved stress tolerance of GroESL-overproducing Lactococcus lactis and probiotic Lactobacillus paracasei NFBC 338. Appl Environ Microbiol 70 (2004), 5929–5936, 10.1128/AEM.70.10.5929-5936.2004.
19. Mills, D.A., Mutagenesis in the post genomics era: tools for generating insertional mutations in the lactic acid bacteria. Curr Opin Biotechnol 12 (2001), 503–509 http://www.ncbi.nlm.nih.gov/pubmed/11604329 (accessed 12.09.17).
20. De Moreno De Leblanc, A., Del Carmen, S., Chatel, J.M., Azevedo, V., Langella, P., Bermudez-Humaran, L., Leblanc, J.G., Evaluation of the biosafety of recombinant lactic acid bacteria designed to prevent and treat colitis. J Med Microbiol 65 (2016), 1038–1046, 10.1099/jmm.0.000323.
21. Waller, M.C., Bober, J.R., Nair, N.U., Beisel, C.L., Toward a genetic tool development pipeline for host-associated bacteria. Curr Opin Microbiol 38 (2017), 156–164, 10.1016/j.mib.2017.05.006.
22. van Pijkeren, J.-P., Neoh, K.M., Sirias, D., Findley, A.S., Britton, R.A., Exploring optimization parameters to increase ssDNA recombineering in Lactococcus lactis and Lactobacillus reuteri. Bioengineered 3 (2012), 209–217, 10.4161/bioe.21049.
23. Oh, J.-H., van Pijkeren, J.-P., CRISPR-Cas9-assisted recombineering in Lactobacillus reuteri. Nucleic Acids Res, 42, 2014, e131, 10.1093/nar/gku623.
24. Kong, W., Kapuganti, V.S., Lu, T., A gene network engineering platform for lactic acid bacteria. Nucleic Acids Res 44 (2015), 1–10, 10.1093/nar/gkv1093 Expanding beyond single gene and promoter manipulation, the PEVLAB system was systematically developed for full gene network manipulation in lactic acid bacteria. A shuttle plasmid with inducible copy control leverages engineering functions in E. coli and can then be integrated into L. lactis. The platform suggests the adoption of multiplex automated genome engineering and ssDNA-based engineering for small parts editing and Red/ET recombineering combined with selection/counter-selection for larger parts.
25. Brophy, J.A.N., Voigt, C.A., Principles of genetic circuit design. Nat Methods 11 (2014), 508–520, 10.1038/nmeth.2926.
26. Ou, B., Yang, Y., Tham, W.L., Chen, L., Guo, J., Zhu, G., Genetic engineering of probiotic Escherichia coli Nissle 1917 for clinical application. Appl Microbiol Biotechnol 100 (2016), 8693–8699, 10.1007/s00253-016-7829-5.
27. Yoon, W., Park, Y.C., Kim, J., Chae, Y.S., Byeon, J.H., Min, S.H., Park, S., Yoo, Y., Park, Y.K., Kim, B.M., Application of genetically engineered Salmonella typhimurium for interferon-gamma-induced therapy against melanoma. Eur J Cancer 70 (2017), 48–61, 10.1016/j.ejca.2016.10.010.
28. Wang, Y., Deng, H., Li, Z., Tan, Y., Han, Y., Wang, X., Du, Z., Liu, Y., Yang, R., Bai, Y., Bi, Y., Zhi, F., Safety evaluation of a novel strain of Bacteroides fragilis. Front Microbiol, 8, 2017, 435, 10.3389/fmicb.2017.00435.
29. Mimee, M., Tucker, A.C., Voigt, C.A., Lu, T.K., Programming a human commensa bacterium, Bacteroides thetaiotaomicron, to sense and respond to stimuli in the murine gut microbiota. Cell Syst 1 (2015), 62–71, 10.1016/j.cels.2015.06.001.
30. Czerkinsky, C., Holmgren, J., Topical immunization strategies. Mucosal Immunol 3 (2010), 545–555, 10.1038/mi.2010.55.
31. Li, Y., Li, X., Liu, H., Zhuang, S., Yang, J., Zhang, F., Intranasal immunization with recombinant Lactococci carrying human papillomavirus E7 protein and mouse interleukin-12 DNA induces E7-specific antitumor effects in C57BL/6 mice. Oncol Lett 7 (2014), 576–582, 10.3892/ol.2013.1743.
32. Rangel-Colmenero, B.R., Gomez-Gutierrez, J.G., Villatoro-Hernández, J., Zavala-Flores, L.M., Quistián-Martínez, D., Rojas-Martínez, A., Arce-Mendoza, A.Y., Guzmán-López, S., Montes-de-Oca-Luna, R., Saucedo-Cárdenas, O., Enhancement of Ad-CRT/E7-mediated antitumor effect by preimmunization with L. lactis expressing HPV-16 E7. Viral Immunol 27 (2014), 463–467, 10.1089/vim.2014.0055.
33. Mansour, N.M., Abdelaziz, S.A., Oral immunization of mice with engineered Lactobacillus gasseri NM713 strain expressing Streptococcus pyogenes M6 antigen. Microbiol Immunol 60 (2016), 527–532, 10.1111/1348-0421.12397.
34. Ma, Y., Liu, J., Hou, J., Dong, Y., Lu, Y., Jin, L., Cao, R., Li, T., Wu, J., Oral administration of recombinant Lactococcus lactis expressing HSP65 and tandemly repeated P277 reduces the incidence of type I diabetes in non-obese diabetic mice. PLoS ONE 9 (2014), 1–10, 10.1371/journal.pone.0105701.
35. Marcobal, A., Liu, X., Zhang, W., Dimitrov, A.S., Jia, L., Lee, P.P., Fouts, T.R., Parks, T.P., Lagenaur, L.A., Expression of human immunodeficiency virus type 1 neutralizing antibody fragments using human vaginal Lactobacillus. AIDS Res Hum Retroviruses, 0, 2016, 10.1089/aid.2015.0378 Recently identified, broadly neutralizing antibodies against epitopes of the HIV-1 viral envelope were made into active antibody fragments and optimally expressed in L. jensenii. While all fragments bound the CD4i sites, the m36.4 antibody also inhibited HIV-1 in a neutralization assay.
36. Borrero, J., Chen, Y., Dunny, G.M., Kaznessis, Y.N., Modified lactic acid bacteria detect and inhibit multiresistant enterococci. ACS Synth Biol 4 (2015), 299–306, 10.1021/sb500090b.
37. Wei, P., Yang, Y., Liu, Z., Huang, J., Gong, Y., Sun, H., Oral Bifidobacterium longum expressing alpha-melanocyte-stimulating hormone to fight experimental colitis. Drug Deliv 23 (2016), 2058–2064, 10.3109/10717544.2015.1122672.
38. Yoon, S.-W., Lee, C.-H., Kim, J.-Y., Kim, J.-Y., Sung, M.-H., Poo, H., Lactobacillus casei secreting alpha-MSH induces the therapeutic effect on DSS-induced acute colitis in Balb/c Mice. J Microbiol Biotechnol 18 (2008), 1975–1983 http://www.ncbi.nlm.nih.gov/pubmed/19131702 (accessed 12.09.17).
39. Liu, S., Li, Y., Deng, B., Xu, Z., Recombinant Lactococcus lactis expressing porcine insulin-like growth factor I ameliorates DSS-induced colitis in mice. BMC Biotechnol, 16, 2016, 25, 10.1186/s12896-016-0255-z.
40. Shigemori, S., Watanabe, T., Kudoh, K., Ihara, M., Nigar, S., Yamamoto, Y., Suda, Y., Sato, T., Kitazawa, H., Shimosato, T., Oral delivery of Lactococcus lactis that secretes bioactive heme oxygenase-1 alleviates development of acute colitis in mice. Microb Cell Fact, 14, 2015, 189, 10.1186/s12934-015-0378-2.
41. Shigemori, S., Ihara, M., Sato, T., Yamamoto, Y., Nigar, S., Ogita, T., Shimosato, T., Secretion of an immunoreactive single-chain variable fragment antibody against mouse interleukin 6 by Lactococcus lactis. Appl Microbiol Biotechnol 101 (2017), 341–349, 10.1007/s00253-016-7907-8.
42. Bermúdez-Humarán, L.G., Motta, J.-P., Aubry, C., Kharrat, P., Rous-Martin, L., Sallenave, J.-M., Deraison, C., Vergnolle, N., Langella, P., Serine protease inhibitors protect better than IL-10 and TGF-β anti-inflammatory cytokines against mouse colitis when delivered by recombinant lactococci. Microb Cell Fact 14 (2015), 26–36, 10.1186/s12934-015-0198-4.
43. del Carmen, S., de, A., de LeBlanc, M., Martin, R., Chain, F., Langella, P., Bermúdez-Humarán, L.G., LeBlanc, J.G., Genetically engineered immunomodulatory Streptococcus thermophilus strains producing antioxidant enzymes exhibit enhanced anti-inflammatory activities. Appl Environ Microbiol 80 (2014), 869–877, 10.1128/AEM.03296-13.
44. Carvalho, R.D., Breyner, N., Menezes-Garcia, Z., Rodrigues, N.M., Lemos, L., Maioli, T.U., da Gloria Souza, D., Carmona, D., de Faria, A.M.C., Langella, P., Chatel, J.-M., Bermúdez-Humarán, L.G., Figueiredo, H.C.P., Azevedo, V., de Azevedo, M.S., Secretion of biologically active pancreatitis-associated protein I (PAP) by genetically modified dairy Lactococcus lactis NZ9000 in the prevention of intestinal mucositis. Microb Cell Fact, 16, 2017, 27, 10.1186/s12934-017-0624-x.
45. Caluwaerts, S., Vandenbroucke, K., Steidler, L., Neirynck, S., Vanhoenacker, P., Corveleyn, S., Watkins, B., Sonis, S., Coulie, B., Rottiers, P., AG013, a mouth rinse formulation of Lactococcus lactis secreting human Trefoil Factor 1, provides a safe and efficacious therapeutic tool for treating oral mucositis. Oral Oncol 46 (2010), 564–570, 10.1016/j.oraloncology.2010.04.008.
46. Limaye, S.A., Haddad, R.I., Cilli, F., Sonis, S.T., Colevas, A.D., Brennan, M.T., Hu, K.S., Murphy, B.A., Phase 1b, multicenter, single blinded, placebo-controlled, sequential dose escalation study to assess the safety and tolerability of topically applied AG013 in subjects with locally advanced head and neck cancer receiving induction chemotherapy. Cancer 119 (2013), 4268–4276, 10.1002/cncr.28365.
47. Duan, F.F., Liu, J.H., March, J.C., Engineered commensal bacteria reprogram intestinal cells into glucose-responsive insulin-secreting cells for the treatment of diabetes. Diabetes 64 (2015), 1794–1803, 10.2337/db14-0635 GLP-1(1-37) has been previously shown to stimulate the reprogramming of rat and human intestinal cells into β-cells that can produce insulin in response to glucose levels. When chromosomally integrated into L. gasseri ATCC 33323 and subsequently fed to diabetic rats, constitutive secretion of GLP-1(1-37) significantly reduced hyperglycemia. The co-expression of β-cell and enteroendocrine markers were observed to measure the extent of reprogramming.
48. Rhimi, M., Bermudez-Humaran, L.G., Huang, Y., Boudebbouze, S., Gaci, N., Garnier, A., Gratadoux, J.-J., Mkaouar, H., Langella, P., Maguin, E., The secreted L-arabinose isomerase displays anti-hyperglycemic effects in mice. Microb Cell Fact, 14, 2015, 204, 10.1186/s12934-015-0391-5.
49. Durrer, K.E., Allen, M.S., Von Herbing, I.H., Genetically engineered probiotic for the treatment of phenylketonuria (PKU); assessment of a novel treatment in vitro and in the PAHenu2 mouse model of PKU. PLOS ONE 12 (2017), 1–17, 10.1371/journal.pone.0176286.
50. Donaldson, G.P., Lee, S.M., Mazmanian, S.K., Gut biogeography of the bacterial microbiota. Nat Rev Microbiol 14 (2015), 20–32, 10.1038/nrmicro3552.
51. Hwang, I.Y., Koh, E., Wong, A., March, J.C., Bentley, W.E., Lee, Y.S., Chang, M.W., Engineered probiotic Escherichia coli can eliminate and prevent Pseudomonas aeruginosa gut infection in animal models. Nat Commun, 8, 2017, 15028, 10.1038/ncomms15028.
52. Kong, W., Blanchard, A.E., Liao, C., Lu, T., Engineering robust and tunable spatial structures with synthetic gene circuits. Nucleic Acids Res 45 (2017), 1005–1014, 10.1093/nar/gkw1045 The dual signaling and antimicrobial features of nisin were leveraged to create a circuit for spatial band-pass protein expression. Green fluorescent protein expression was induced using the NICE system in which an external nisin concentration gradient determined circuit outcome. Nisin-producing cells and nisin-sensitive responder cells were mixed to produce various spatial patterns by observing green or red fluorescence.
53. Chan, C.T.Y., Lee, J.W., Cameron, D.E., Bashor, C.J., Collins, J.J., Deadman” and “Passcode” microbial kill switches for bacterial containment. Nat Chem Biol 12 (2015), 82–86, 10.1038/nchembio.1979.
54. Riglar, D.T., Giessen, T.W., Baym, M., Kerns, S.J., Niederhuber, M.J., Bronson, R.T., Kotula, J.W., Gerber, G.K., Way, J.C., Silver, P.A., Engineered bacteria can function in the mammalian gut long-term as live diagnostics of inflammation. Nat Biotechnol 35 (2017), 653–658, 10.1038/nbt.3879 The mouse commensal strain E. coli NGF-1 was conferred with a memory switch and an environmental response trigger. Here, Cro protein expression was driven by tetrathionate, a product of ROS during inflammation. A phage-lambda-based CI/Cro memory switch was turned on along with lacZ expression. This was able to measure subclinical inflammation in a TRUC mouse model and was retained in the off state for 200 days.
55. Danino, T., Prindle, A., Kwong, G.A., Skalak, M., Li, H., Allen, K., Hasty, J., Bhatia, S.N., Programmable probiotics for detection of cancer in urine. Sci Transl Med, 7, 2015, 289ra84, 10.1126/scitranslmed.aaa3519.
56. Food and Drug Administration, Enforcement Policy Regarding Investigational New Drug Requirements for Use of Fecal Microbiota for Transplantation to Treat Clostridium Difficile Infection not Responsive to Standard Therapies. 2016 http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guida (accessed 13.09.17).
57. Microbiome Therapeutics and Diagnostics Market. edn 2, 2017 2017–2030 https://www.researchandmarkets.com/research/pdt2pm/microbiome.